Transgene S.A.
TRGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $4,579 | $284 | $23 | $3,137 |
| % Growth | 1,512.3% | 1,134.8% | -99.3% | – |
| Cost of Goods Sold | $17,910 | -$15,423 | $15,423 | $14,019 |
| Gross Profit | -$13,331 | $15,707 | -$15,400 | -$10,882 |
| % Margin | -291.1% | 5,530.6% | -66,956.5% | -346.9% |
| R&D Expenses | $17,910 | $18,855 | $15,423 | $17,314 |
| G&A Expenses | $3,783 | -$4,554 | $4,558 | $3,736 |
| SG&A Expenses | $3,783 | -$4,537 | $4,541 | $3,736 |
| Sales & Mktg Exp. | $0 | $17 | -$17 | $0 |
| Other Operating Expenses | -$17,964 | $17,218 | -$15,535 | -$17,218 |
| Operating Expenses | $3,729 | $31,536 | $4,429 | $3,832 |
| Operating Income | -$17,060 | -$15,829 | -$19,829 | -$14,714 |
| % Margin | -372.6% | -5,573.6% | -86,213% | -469% |
| Other Income/Exp. Net | -$2,235 | $1,550 | $137 | $8,288 |
| Pre-Tax Income | -$19,295 | -$14,279 | -$19,692 | -$6,426 |
| Tax Expense | $0 | $3,207 | -$3,207 | $0 |
| Net Income | -$19,295 | -$17,486 | -$16,485 | -$6,426 |
| % Margin | -421.4% | -6,157% | -71,673.9% | -204.8% |
| EPS | -0.15 | -0.18 | -0.16 | -0.063 |
| % Growth | 16.7% | -12.5% | -152.4% | – |
| EPS Diluted | -0.15 | -0.18 | -0.16 | -0.063 |
| Weighted Avg Shares Out | 128,633 | 100,957 | 100,957 | 101,384 |
| Weighted Avg Shares Out Dil | 132,513 | 100,957 | 100,957 | 101,383 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $311 | $8,289 |
| Interest Expense | $697 | -$542 | $542 | $0 |
| Depreciation & Amortization | $650 | $675 | $606 | $1,215 |
| EBITDA | -$16,410 | -$8,108 | -$18,544 | -$13,464 |
| % Margin | -358.4% | -2,854.9% | -80,626.1% | -429.2% |